Quantcast
Browsing latest articles
Browse All 3 View Live

Kadimastem plans stem cell therapy trial for ALS in late 2016

Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for Amyotrophic Lateral...

View Article

Browsing latest articles
Browse All 3 View Live